Melane Sampson, Author at BioTuesdays

Developments

PolTREG initiates Phase 2 trial of PTG-007 targeting functional cure for children at risk of T1D

PolTREG (WSE:PTG) has launched a Phase 2 clinical trial of PTG-007, a polyclonal autologous Treg cellular therapy, in children with presymptomatic Type-1 diabetes (T1D), following approval from the European Medicines...

October 24, 2024

Executive Moves

Dr. Makoto Kuro-o joins Klotho as scientific advisor

Klotho Neurosciences (NASDAQ:KLTO) has appointed Makoto Kuro-o, MD, Ph.D., to its scientific advisory board. Dr. Kuro-o, a pioneer in the discovery of the anti-aging Klotho (s-KL) gene, will support Klotho’s mission to...

October 23, 2024

Developments

Olema reports compelling preclinical data on OP-3136’s anti-tumor activity

Olema Oncology (NASDAQ:OLMA) has announced results from three preclinical studies demonstrating the robust anti-tumor activity of OP-3136 as a single agent and in combination with palazestrant. The results will be...

October 23, 2024

Developments

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

Ocugen (NASDAQ:OCGN) has announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of its Phase 1/2 clinical trial of OCU410ST GARDian for Stargardt disease. The GARDian...

October 22, 2024

Developments

SIGA signs licencing agreement with Vanderbilt U for mAbs portfolio

SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential...

October 22, 2024

Developments

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Closely-held MOBILion Systems has announced a novel, next-generation high-resolution mass spectrometry approach for complex sample analysis, delivering unprecedented speed, sensitivity, specificity, and quantitative...

October 21, 2024

Developments

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...

October 21, 2024

Developments

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

PolyPid (NASDAQ:PYPD) has announced the publication of a study in the International Journal of Surgery (IJS), showcasing the full data set from its Phase 3 SHIELD I trial of D-PLEX, focused on preventing surgical site...

October 21, 2024

Developments

Celularity expands portfolio acquiring Rebound from Sequence

Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...

October 17, 2024

Developments

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

Theriva Biologics (NYSE American:TOVX) has announced that the European Commission (EC) has adopted the European Medicines Agency’s (EMA) recommendation to grant orphan medicinal product designation to its lead...

October 16, 2024

Author - Melane Sampson

PolTREG initiates Phase 2 trial of PTG-007 targeting functional cure for children at risk of T1D

Dr. Makoto Kuro-o joins Klotho as scientific advisor

Olema reports compelling preclinical data on OP-3136’s anti-tumor activity

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

SIGA signs licencing agreement with Vanderbilt U for mAbs portfolio

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

Celularity expands portfolio acquiring Rebound from Sequence

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

General

More